fclitloan

The Bispecific Antibody Therapeutics Market is projected to grow at an annualized rate of ~16%, in the span of 2019 to 2030

The Bispecific Antibody Therapeutics Market is projected to grow at an annualized rate of ~16%, in the span of 2019 to 2030

Roots Analysis has done a detailed study on (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

For more information, please visit

Table of Contents

4 MARKET OVERVIEW

4.1. 牋牋牋牋牋牋牋牋牋 Chapter Overview

4.2. 牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Developer Landscape

4.2.1.牋牋牋牋牋牋牋牋 Analysis by Year of Establishment

4.3. 牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Clinical Pipeline

4.3.2.牋牋牋牋牋牋牋牋 Analysis by Target Antigen

4.3.5.牋牋牋牋牋牋牋牋 Analysis by Disease Indication

4.3.7.牋牋牋牋牋牋牋牋 Analysis by Broader Disease Segment

4.3.9.牋牋牋牋牋牋牋牋 Analysis by Mode of Administration

4.3.10.牋牋牋牋牋牋牋 Analysis by Patient Segment

4.4. 牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Early Stage Pipeline

4.4.2.牋牋牋牋牋牋牋牋 Analysis by Target Antigen

4.4.6.牋牋牋牋牋牋牋牋 Analysis by Broader Disease Segment

4.6. 牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Combination Therapy Candidates

4.7.牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Non-Industry Players

4.8.牋牋牋牋牋牋牋牋牋 Emerging Novel Antibody Therapeutic Modalities

5牋 Bispecific Antibody Therapeutics: Technology Platforms牋

5.1.牋牋牋牋牋牋牋牋牋 Chapter Overview

5.2.牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: List of Technology Platforms

5.3.牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Technology Platform Profiles

5.3.3.牋牋牋牋牋牋牋牋 Xmab™ Antibody Engineering Platform (Xencor)

5.3.4.牋牋牋牋牋牋牋牋 WuXibodyTM Bispecific Engineering Platform (WuXi Biologics)

5.3.6.牋牋牋牋牋牋牋牋 Azymetric™ (Zymeworks)

5.4.牋牋牋牋牋牋牋牋牋 Geographical Distribution of Technology Providers

5.5.牋牋牋牋牋牋牋牋牋 Bispecific Antibody Technology Platforms: Comparative Analysis

6牋 DRUG PROFILES 

6.1.牋牋牋牋牋牋牋牋牋 Chapter Overview

6.2.牋牋牋牋牋牋牋牋牋 Marketed Drug Profiles

6.2.1.牋牋牋牋牋牋牋牋 Blincytolaoji.org™ / Blinatumomab / AMG103 / MT103 (Amgen)

6.2.1.1.1. Financial Performance牋牋牋牋

6.2.1.2.1. Mechanism of Action and Targets牋

6.2.1.2.3. Current Development Status

6.2.1.2.4. Development Process

6.2.2.1.1. Financial Performance牋牋牋牋

6.2.2.2.1. Mechanism of Action and Targets牋

6.2.2.2.4. Development Process

6.3.牋牋牋牋牋牋牋牋牋 Late Stage Drug Profiles

6.4.1 牋牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.5.牋牋牋牋牋牋牋牋牋 Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals)

6.5.1 牋牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.7.牋牋牋牋牋牋牋牋牋 ABY-035 (Affibody)牋

6.7.1.牋牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.9.1.牋牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.10.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.11.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.12.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.13.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.14.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.15.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.17.1.牋牋牋牋牋牋牋 Drug Overview牋牋牋牋

6.18.1.牋牋牋牋牋牋牋 Drug Overview

7牋 KEY INSIGHTS

7.1.牋牋牋牋 Chapter Overview

7.2.牋牋牋牋 Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development牋

7.5.牋牋牋牋牋牋牋牋牋 Logo Landscape: Analysis of Developers by Company Size牋牋

8牋 BENCHMARK ANALYSIS: BIG PHARMA PLAYERS

8.1. 牋牋牋牋牋牋牋牋牋 Chapter Overview

8.2. 牋牋牋牋牋牋牋牋牋 Top Pharmaceutical Companies

8.2.2.牋牋牋牋牋牋牋牋 Analysis by Type of Antibody Format

8.2.3.牋牋牋牋牋牋牋牋 Analysis by Mechanism of Action

8.2.4.牋牋牋牋牋牋牋牋 Analysis by Therapeutic Area

8.2.5.牋牋牋牋牋牋牋牋 Analysis by Type of Partnership

9牋 PARTNERSHIPS AND COLLABORATIONS

9.1.牋牋牋牋牋牋牋牋牋 Chapter Overview

9.2.牋牋牋牋牋牋牋牋牋 Partnership Models

9.3.牋牋牋牋牋牋牋牋牋 Bispecific Antibody Therapeutics: Partnerships and Collaborations

9.3.1.牋牋牋牋牋牋牋牋 Analysis by Year of Partnership

9.3.2.牋牋牋牋牋牋牋牋 Analysis by Type of Partnership

9.3.3.牋牋牋牋牋牋牋牋 Analysis by Therapeutic Area

9.3.4.牋牋牋牋牋牋牋牋 Most Active Developers: Analysis by Number of Partnerships

9.3.5.牋牋牋牋牋牋牋牋 Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements牋牋牋

9.3.6.牋牋牋牋牋牋牋牋 Regional Analysis

9.3.7.牋牋牋牋牋牋牋牋 Intercontinental and Intracontinental Agreements

10 CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS

10.2.1.牋牋牋牋牋牋牋 Key Manufacturing Considerations and Challenges

10.2.2.牋牋牋牋牋牋牋 Contract Manufacturing Organizations (CMOs)

10.2.3.牋牋牋牋牋牋牋 Contract Research Organizations (CROs)

For more information, please click on the following link:

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

About Roots Analysis

is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com